Publications
Breast
Oestrogen receptor concentration in primary breast cancer and axillary node metastases.
Hawkins RA, Black R, Steele RJC, Dixon JM and Forrest APM.
Breast Cancer Research and Treatment 1981; 1: 245-251.
Infiltrating lobular carcinoma of the breast.
Dixon JM, Anderson TJ, Page DL, Lee D, and Duffy SW.
Histopathology 1982; 6: 149-161.
Mammary duct ectasia.
Dixon JM, Anderson TJ, Lumsden AB, Elton RA, Roberts MM and
Forrest APM.
British Journal of Surgery 1983; 70: 601-603.
The morphological basis of human breast cyst populations.
Dixon JM, Miller WR, Scott WN and Forrest APM.
British Journal of Surgery 1983; 70: 604-606.
Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of
bilateral disease.
Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW and Stewart HJ.
British Journal of Surgery 1983; 70: 513-516.
The advantage of adrenaline in local and general anaesthetic breast biopsy.
Dixon JM, Crofts TJ, Armstrong CP, Lee D, Wilson J and Forrest
APM.
Journal of the Royal College of Surgeons of Edinburgh 1983; 28: 292-294.
Fine needle aspiration of the breast: the importance of the aspirator.
Dixon JM, Lamb J and Anderson TJ.
Lancet 1983; ii: 564.
Classification of human breast cysts according to electrolyte and androgen conjugate
composition.
Miller WR, Dixon JM, Scott WN and Forrest APM.
Clinical Oncology 1983; 9: 227-232.
Invasive cribriform carcinoma of the breast.
Page DL, Dixon JM, Anderson TJ, Lee D and Stewart HJ.
Histopathology 1983; 7: 525-536.
Adrenaline in breast biopsy
Dixon JM.
Wrexham Medical Journal 1983; 11: 4-10.
Polyamines in breast cancer.
Kingsnorth AN, Wallace H, Bundred NJ and Dixon JM.
British Journal of Surgery 1984; 71: 352-356.
1
Fine needle aspiration cytology in relationship to clinical examination and mammography in
the diagnosis of a solid breast mass.
Dixon JM, Anderson TJ, Lamb J, Nixon SJ and Forrest APM.
British Journal of Surgery 1984; 71: 593-596.
pH of human breast cyst fluids.
Dixon JM, Scott WN and Miller WR.
Clinical Oncology 1984; 10: 221-224.
Clinical assessment of tumour size in primary breast carcinoma.
Dixon JM, Senbanjo R, Anderson TJ, Elton RA and Forrest APM.
Clinical Oncology 1984; 10: 117-122.
Human breast cystic disease.
Dixon JM and Miller WR.
Breast News 1984; 1: 608.
Mammary duct ectasia - studies of factors involved in its aetiology and pathogenesis.
Dixon JM and Bundred NJ.
Breast News 1984; 4: 1-5.
Natural history of cystic disease: importance of cyst type.
Dixon JM, Scott WN and Miller WR.
British Journal of Surgery 1985; 72: 190-192.
Long term survivors from breast cancer.
Dixon JM, Lee D, Page DL, Anderson TJ, Elton RA, Stewart HJ
and Forrest APM,
British Journal of Surgery 1985; 72: 445-448.
Are the lesions of duct ectasia sterile?
Bundred NJ, Dixon JM, Lumsden AB, Radford D, Hood J, Miles RS,
Chetty U and Forrest APM.
British Journal of Surgery 1985; 72: 844-845.
The relationship of cyst type to risk factors for breast cancer and subsequent development of
breast cancer in patients with breast cystic disease.
Dixon JM, Lumsden AB and Miller WR.
European Journal of Cancer and Clinical Oncology 1985; 21: 10471050.
An analysis of the content and morphology of human breast microcysts.
Dixon JM, Scott WN and Miller WR.
European Journal of Surgical Oncology 1985; 11: 151-154.
Androgen receptor activity in human breast cancer and its relationship with oestrogen and
progestogen receptor activity.
Miller WR, Telford J, Dixon JM and Hawkins RA.
European Journal of Cancer 1985; 21: 539-542.
Androgen metabolism and apocrine differentiation in human breast cancer.
Miller WR Telford J, Dixon JM and Shivas AA.
Breast Cancer Research and Treatment 1985; 5: 67-73.
2
Fine needle aspiration of breast cancer: relationship of clinical factors to cytology results in
689 primary malignancies.
Barrows GM, Anderson TJ, Lamb J and Dixon JM.
Cancer 1986; 58: 1493-1498.
Hormonal correlates of apocrine secretion in the breast.
Miller WR, Dixon JM and Forrest APM.
Annals of New York Academy of Science 1986; 464: 275-287.
Primary lymphoma of the breast.
Dixon JM, Chetty U and Forrest APM.
British Journal of Surgery 1987; 74: 214-217.
Mammillary fistula.
Bundred NJ, Dixon JM, Chetty U and Forrest APM.
British Journal of Surgery 1987; 74: 466-468.
Prognostic significance of oestrogen and progestogen receptor activities in breast cancer.
Hawkins RA, White G, Bundred NJ, Dixon JM, Miller WR, Stewart HJ
and Forrest APM.
British Journal of Surgery 1987; 74: 1009-1013.
Reduction in the biopsy rate in benign breast disease using fine needle aspiration cytology
with immediate reporting.
Dixon JM, Clarke PJ, Crucioli V, Dehn TCB, Lee ECG and Greenall MJ.
British Journal of Surgery 1987; 74: 1014-1016.
Fine needle aspiration cytology with immediate reporting in the outpatient diagnosis of breast
disease.
Dehn TCB, Clarke PJ, Dixon JM, Crucioli V, Greenall MJ and Lee ECG.
Annals of the Royal College of Surgeons of England 1987: 6: 280-282.
The role of FNA cytology in breast cancer screening.
Lamb J, Anderson TJ, Dixon JM and Levack P.
Journal of Clinical Pathology 1987; 7: 705-709.
Repeated aspiration of breast abscesses in lactating women.
Dixon JM.
British Medical Journal 1988; 297: 1517-1518.
Wound infection after breast biopsy.
Dixon JM, Chetty U and Forrest APM.
British Journal of Surgery 1988; 75: 918-919.
Treatment of periareolar inflammation associated with periductal mastitis using
Metronidazole and Flucloxacillin: a preliminary report.
Dixon JM, Lee ECG and Greenall MJ.
British Journal of Clinical Practice 1988; 42: 78-80.
Periductal mastitis - aetiology and management.
Dixon JM.
British Journal of Clinical Practice 1989; 43 (suppl 68): 76-80.
3
Pathogenesis of cystic disease.
Dixon JM.
British Journal of Clinical Practice 1989; 43 (suppl 68): 90-93.
Periductal mastitis/duct ectasia.
Dixon JM.
World Journal of Surgery 1989; 13: 715-720.
The H-ras oncogene product p21 and prognosis in human breast cancer.
Watson DMA, Elton RA, Jack WJ, Dixon JM and Miller WR.
Breast Cancer Research and Treatment 1990; 17: 161-169.
Cyclic AMP binding protein and prognosis in breast cancer.
Miller WR, Elton RA, Dixon JM, Chetty U and Watson DM.
British Journal of Cancer 1990; 61: 263-266.
Mammography in the management of patients with small breast cancers.
Dixon JM and Chetty U.
British Journal of Surgery 1991; 78: 218-219.
Colour flow Doppler studies of benign and malignant breast lesions.
Dixon JM and Walsh J.
British Journal of Surgery 1991; 78: 259-260.
Effective surgical treatment for mammillary fistula.
Dixon JM and Thompson AM.
British Journal of Surgery 1991; 78: 1185-1186.
Wound compression pads are of no value after local anaesthetic breast biopsy.
Johnston AJ, Thompson AM, John TG, Charles MH and Dixon JM.
Annals of the Royal College of Surgeons of England 1991; 73: 303-304.
Immediate reporting of fine needle aspiration cytology of breast lesions.
Dixon JM.
British Medical Journal 1991; 302: 428-429.
Breast lumps: when there is no need to worry.
Travis H and Dixon JM.
Family Circle Magazine 1991; 82.
Nomenclature of benign breast disorders: Report of a working party on the rationalisation of
concepts and terminology of benign breast conditions.
Hughes LE, Smallwood JA and Dixon JM.
The Breast 1992; 1: 15-17.
Marking of excision specimens in patients undergoing stereotactic wide local excision for
breast cancer.
Nedelman R and Dixon JM.
British Journal of Surgery 1992; 79: 55.
Outpatient treatment of non-lactating breast abscesses.
Dixon JM.
4
British Journal of Surgery 1992; 79: 56-57.
PDS IIR (Polydioxanone) is the monofilament suture of choice for subcuticular wound
closure following breast biopsy.
Johnstone AJ, John TG, Thompson AM, Charles MH and Dixon JM.
Journal of the Royal College of Surgeons of Edinburgh 1992; 37: 94-96.
Colour Doppler studies of axillary nodes in patients with breast cancer.
Walsh J, Dixon JM, Paterson D and Chetty U.
British Journal of Radiology 1992; 65: 142.
Treatment of elderly patients with breast cancer.
Dixon JM.
British Medical Journal 1992; 304: 996-997.
Morbidity after breast biopsy for benign disease in a screened population.
Dixon JM, John TG.
Lancet 1992; 339: 128.
Specimen-orientated radiography helps define excision margins of malignant lesions detected
by breast screening.
Dixon JM, RaviSekar O, Walsh J, Paterson D and Anderson TJ.
British Journal of Surgery 1993; 80: 1001-1002.
Importance of interpectoral nodes in breast cancer.
Dixon JM and Dobie V.
European Journal of Cancer 1993; 29: 334-336.
Indications for and techniques of breast biopsy.
Dixon JM.
Current Practice in Surgery 1993; 5: 142-148.
Screening for breast cancer.
Dixon JM.
British Journal of Surgery 1993; 80: 141-142.
Wisdom of cancer screening II.
Dixon JM and Dunlop MG.
Surgery 1993; 11: 343-344.
Infusional 5 fluorouracil given as a single agent in relapsed breast cancer: its activity and
toxicity.
Ng JSY, Cameron DA, Lee L, Dixon JM and Leonard RCF.
The Breast 1994; 3: 87-89.
Expression of transforming growth factor beta mRNA isoforms in human breast cancer.
MacCallum J, Bartlett JMS, Thompson AM, Keen JC, Dixon JM and
Miller WR.
British Journal of Cancer 1994; 69: 1006-1009.
P-glycoprotein and resistance to tamoxifen.
Keen JC, Miller EP, Bellamy C, Dixon JM, Miller WR.
Lancet 1994; 343: 1047-1048.
5
Colour Doppler studies of axillary node metastases in breast carcinoma.
Walsh JS, Dixon JM, Chetty U and Paterson D.
Clinical Radiology 1994; 49: 189-191.
Consensus document on staging for breast cancer.
Yarnold J, Dixon JM and Greco M on behalf of the European Society
of Mastology.
The Breast 1994; 3: 238-240
Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene
mutation in families linked to BRCA1 on chromosome 17q12-21.
Porter DE, Cohen BB, Wallace MR, Carothers A, Smyth E, Chetty U,
Dixon JM, Steel CM and Carter DC.
British Journal of Surgery 1994; 81: 1512-1515.
ABC of breast diseases: symptoms, assessment and guidelines for referral.
Dixon JM and Mansel RE.
British Medical Journal 1994; 309: 722-726.
ABC of breast diseases: congenital problems and aberrations of normal development and
involution.
Dixon JM and Mansel RE.
British Medical Journal 1994; 309: 797-800.
ABC of breast diseases: breast infection.
Dixon JM.
British Medical Journal 1994; 309: 946-949.
ABC of breast diseases: breast cancer - epidemiology, risk factors and genetics.
McPherson K, Steel CM and Dixon JM.
British Medical Journal 1994; 309: 1003-1006.
ABC of breast diseases: screening for breast cancer.
Blamey RW, Wilson ARM, Patnick J and Dixon JM.
British Medical Journal 1994; 309: 1076-1079.
ABC of breast diseases: breast cancer.
Sainsbury JRC, Anderson TJ, Morgan DAL and Dixon JM.
British Medical Journal 1994; 309: 1150-1153.
ABC of breast diseases: management of regional nodes in breast cancer.
Bundred NJ, Morgan DAL and Dixon JM.
British Medical Journal 1994; 309: 1222-1225.
ABC of breast diseases: breast cancer: treatment of elderly patients and uncommon
conditions.
Dixon JM, Sainsbury JRC and Rodger A.
British Medical Journal 1994; 309: 1292-1295.
ABC of breast diseases: role of systemic therapy in primary operable breast cancer.
Richards MA, Smith IE and Dixon JM.
British Medical Journal 1994; 309: 1363-1366.
6
ABC of breast diseases: locally advanced breast cancer.
Rodger A, Leonard RCF and Dixon JM.
British Medical Journal 1994; 309: 1431-1433.
ABC of breast diseases: metastatic breast cancer.
Leonard RCF, Rodger A and Dixon JM.
British Medical Journal 1994; 309: 1501-1504.
ABC of breast diseases: prognostic factors.
Miller WR, Ellis IO, Sainsbury JRC and Dixon JM.
British Medical Journal 1994; 309:1573-1576 .
ABC of breast diseases: management of carcinoma in situ and patients at "high risk" of
subsequent breast cancer.
Page DL, Steel CM and Dixon JM.
British Medical Journal 1995; 310: 39-42.
ABC of breast diseases: breast reconstruction following surgery for breast cancer.
Watson JD, Sainsbury JRC and Dixon JM.
British Medical Journal 1995; 310: 117-121.
Surgical morbidity following primary systemic therapy for breast cancer: a randomised study.
Forouhi P, Dixon JM, Leonard RCF and Chetty U.
British Journal of Surgery 1995; 82: 79-81.
Transforming growth factor ß1 is unlikely to mediate p53 abnormalities in breast cancer.
Thompson AM, Steel CM, Chetty U, Dixon JM and Carter DC.
British Journal of Surgery 1995; 82: 210-211.
Breast reconstruction (leading article).
Dixon JM.
British Journal of Surgery 1995; 82: 865-866.
Role of axillary dissection in women with early breast cancer.
Dixon JM.
Current Medical Literature: Breast and Prostate 1995: 3-8.
Surgery and radiotherapy for early breast cancer (editorial)
Dixon JM.
British Medical Journal 1995; 311: 1515-1516.
Common surgical ailments: breast cysts.
Dixon JM.
Current Practice in Surgery 1995; 7: 118-122.
Assessment of the acceptability of conservative management of fibroadenoma of the breast.
Dixon JM, Dobie V, Lamb J, Walsh JS, Chetty U.
British Journal of Surgery 1996; 83: 264-265.
Breast conserving surgery plus radiation therapy was as effective as mastectomy.
Dixon JM.
7
Evidence Based Medicine 1996; 1: 49.
Different local therapies for early breast cancer do not affect overall survival.
Dixon JM.
Evidence Based Medicine 1996; 1: 118.
Solid-phase extraction and high performance liquid chromatography determination of
tamoxifen and its major metabolites in plasma.
MacCallum J, Cummings, J, Dixon JM and Miller WR.
Journal of Chromatography B: Biomedical Applications 1996; 678: 317-323.
Periductal mastitis and duct ectasia: different conditions with different aetiologies.
Dixon JM, RaviSekar O, Chetty U and Anderson TJ.
British Journal of Surgery 1996; 83: 820-822.
Factors affecting outcome of patients with impalpable breast cancers detected by breast
screening.
Dixon JM, RaviSekar O, Cunningham M, Anderson EDC, Anderson TJ and Brown
HK.
British Journal of Surgery 1996; 83: 997-1001.
Changes in expression of transforming growth factor beta mRNA isoforms in patients
undergoing tamoxifen therapy.
MacCallum J, Keen JC, Bartlett JMS, Thompson AM, Dixon JM, Miller WR.
British Journal of Cancer 1996; 74: 474-478.
Prospective evaluation of prognostic factors in operable breast cancer.
Hawkins RA, Tesdale AL, Killen ME, Jack WJL, Chetty U, Dixon JM,
Hulme MJ, Prescott RJ, McIntyre MA, Miller WR.
British Journal of Cancer 1996; 74: 1469-1478.
Removing bias in surgical trials (editorial).
Johnson AG, Dixon JM.
British Medical Journal 1997; 314: 916-917.
Uptake of dehydroepiandrostene sulphate into human breast cyst fluids.
Dixon JM, Telford J, Elton RA, Miller WR.
The Breast 1997; 6: 12-16.
Pleurocutaneous fistula as a complication of radiation treatment in locally advanced breast
cancer.
Samuel LM, Kunkler IH, Dixon JM, Walker WS.
Journal of the Royal College of Surgeons of Edinburgh 1997; 42: 138-139.
Expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly
patients with breast cancer.
Keen JC, Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, Bellamy C, Miller
WR.
Breast Cancer Research and Treatment 1997; 44: 123-133.
Regulation of aromatase activity within the breast.
Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM and Telford J.
8
Journal of Steroid Biochemistry and Molecular Biology 1997; 61: 193-202.
Breast reconstruction after mastectomy.
Dixon JM.
Pulse 1997; April: 100.
Ovarian ablation in early breast cancer: overview of the randomised trials.
Dixon JM.
Evidence Based Medicine 1997; 2: 75.
Patterns of recurrence of breast cancer following breast-conserving treatment.
Norman B, Dixon JM.
The Breast 1998; 7: 106-107.
Periductal mastitis and duct ectasia: an update.
Dixon JM.
The Breast 1998; 7: 128-130.
Axillary node sampling in breast cancer: an assessment of its efficacy.
Dixon JM, Dillon P, Anderson TJ, Chetty U.
The Breast 1998; 7: 206-208.
Morbidity related to intercostobrachial nerve damage following axillary surgery for breast
cancer.
Maycock, LA, Dillon P, Dixon JM.
The Breast 1998; 7: 209-212.
Total duct excision.
Dixon JM, Kohlhardt SR, Dillon P.
The Breast 1998; 7: 216-219.
Sentinel node biopsy in breast cancer (editorial)
Dixon JM.
British Medical Journal 1998; 317: 295-296.
Breast disease
Dixon JM.
GP 1998; 14 August: 32.
Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous
oestrogen levels within the breast.
Miller WR, Telford J, Love CDB, Leonard RCF, Hillier S, Gundacker H,
Smith H, Dixon JM.
The Breast 1998; 7: 273-276.
Ductal carcinoma in situ of the breast (editorial).
Dixon JM and Page DL.
The Breast 1998; 7: 239-242.
Angiogenesis and breast cancer.
Marson LP, Miller WR and Dixon JM.
9
The Breast 1998; 7: 299-307.
Clinical importance of intratumoural aromatase.
Miller WR, Mullen P, Telford J, Dixon JM.
Breast Cancer Research and Treatment 1998; 49 (suppl 1): S27-32. .
Hormone treatments in breast cancer.
Dixon JM.
Breast News 1998.
Accuracy of intraoperative frozen-section analysis of axillary nodes
Dixon JM, Mamman U, Thomas J.
British Journal of Surgery 1999; 86: 392-395.
Risk of breast cancer in women with palpable breast cysts.
Dixon JM, McDonald C, Elton RA, Miller WR.
The Lancet 1999; 353: 1742-1745.
Managing breast pain.
Dixon JM.
The Practitioner 1999; 243: 484-491.
Preservation of the intercostobrachial nerve during axillary node clearance for breast cancer
reduced sensory deficits.
Dixon JM.
Evidence Based Medicine 1999; 4: 85.
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Dixon JM, Love CDB, Renshaw L, Bellamy C, Cameron DA, Miller WR.
Leonard RCF.
Endocrine Related Cancer 1999; 6: 227-230.
An investigation of endometrial abnormalities in asymptomatic women on tamoxifen and an
evaluation of the role of endometrial screening.
Love CDB, Muir BB, Scrimgeour JB, Leonard RCF, Dixon JM.
Journal of Clinical Oncology 1999; 17 (7): 2050-2054.
Radiotherapy and tamoxifen after surgery improved local control and survival in breast
cancer.
Dixon JM.
Evidence Based Medicine 1999; 4: 183.
Palpable cysts were associated with an increased risk for breast cancer.
Dixon JM, McDonald C, Elton RA, Miller WR.
Evidence Based Medicine 1999; 4: 192.
Estrone and estradiol metabolims in vivo in human breast cysts.
Raju U, Sepkovic DW, Miller WR, Dixon JM, Bradlow HL, Levitz M.
Steroids 2000; 65: 883-888.
Antiaromatase agents: preclinical data and neoadjuvant therapy.
Miller WR, Dixon JM.
Clin Breast Cancer 2000; Suppl 1: S9-S14.
10
Treating young patients with breast cancer.
Dixon JM, Hortobagyi GN.
BMJ 2000; 320: 457-458.
Localization of breast lesions shown only on MRI – a review for the UK study of MRI
Screening for breast cancer.
Warren RML, Hayes C and the Advisory Group of the UK Study of MRI
Screening for Breast Cancer (MARIBS).
British Journal of Radiology 2000; 73: 123-132.
Rationale for a national multi-centre study of magnetic resonance imaging (MRI) screening in
women at genetic risk of breast cancer.
Brown J, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles RA, Evans
DGR, Gilbert FG, Hayes C, Jenkins JPR, Leach MO, Moss SM, Padhani AP, Pointon
LJ, Ponder BAJ, Sloane JP, Turnbull LW, Walker LG, Warren RML, Watson W.
The Breast 2000; 9: 72-77.
Protocol for a national multi-centre study of magnetic resonance imaging (MRI) screening in
women at genetic risk of breast cancer.
Brown J, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles RA, Evans
DGR, Gilbert FG, Hayes C, Jenkins JPR, Leach MO, Moss SM, Padhani AP, Pointon
LJ, Ponder BAJ, Sloane JP, Turnbull LW, Walker LG, Warren RML, Watson W.
The Breast 2000; 9: 78-82
Thickened endometrium caused by tamoxifen returns to normal following tamoxifen
cessation.
Love CDB, Dixon JM.
The Breast 2000; 9: 156-157.
The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal
women with breast cancer: a randomized, double-blind, single-center study.
Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR.
Clinical Cancer Research 2000; 6: 2229-2235.
Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic
changes.
Cameron DA, Keen JC, Dixon JM, Bellamy C, Hanby A, Anderson TJ,
Miller WR.
European Journal of Cancer 2000; 36: 845-851.
Data on effect of HRT on breast cancer conflict with other data.
Vidya R, Dixon JM.
BMJ 2000; 321: 179.
Antiproliferative effect of idoxifene in a placebo-controlled trial in primary human breast
cancer.
Dowsett M, Dixon JM, Horgan K, Salter J, Hills M and Harvey E.
Clinical Cancer Research 2000; 6: 2260-2267.
Ductal carcinoma in situ revisited.
Dixon JM, Page DL.
The Breast 2000; 9: 175-176.
11
Concentrations of tamoxifen and its major metabolites in hormone sensitive breast tumours.
MacCallum J, Dixon JM.
British Journal of Cancer 2000; 82: 1629-1635. .
Gynaecomastia: when is action required?
Macmillan D, Dixon JM.
The Practitioner 2000; 244: 785-787.
ABC of Breast Diseases: Breast cancer – epidemiology, risk factors and genetics.
McPherson K, Steel CM, Dixon JM.
BMJ 2000; 321: 624-628.
Breast cancer: detection and management.
Lambah A, Dixon JM.
The Practitioner 2000; 244: 884-898.
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and
analysis protocol for the UK multicentre study.
Brown J, Buckley D, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles
RA, Evans DGR, Gilbert FG, Grabves M, Hayes C, Jenkins JPR, Jones
AP, Keevil SF, Leach MO, Liney GP, Moss SM, Padhani AR, Parker GJM, Pointon
LJ, Ponder BAJ, Tredpath TW, Sloane JP, Turnbull LW, Walker LG, Warren RML.
Magnetic Resonance Imaging 2000; 18: 765-776.
Charity spice
Dixon JM.
BMJ 2000; 321: 1479.
The truth about breast cancer.
Dixon JM.
Women’s Health Letter 2001; 10, 4-6.
Clinical update: fibroadenoma of the breast.
Houssami N, Cheung M, Dixon JM.
Medical Journal of Australia 2001; 174: 185-188.
Letrozole as primary medical therapy for locally advanced and large operable breast cancer.
Dixon JM, Love CDB, Bellamy COC, Cameron DA, Leonard RCF, Smith
H, Miller WR.
Breast Cancer Research and Treatment 2001; 66 (3): 191-199.
Hormone replacement therapy and the breast.
Dixon JM.
BMJ 2001; 323: 1381-1382.
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Miller WR, Dixon JM, Cameron DA, Anderson TJ.
Journal of Steroid Biochemistry & Molecular Biology 2001; 79: 103-107.
Local endocrine effects of aromatase inhibitors within the breast.
Miller WR, Dixon JM.
12
The Journal of Steroid Biochemistry & Molecular Biology 2001; 79: 93-102.
Is lactation mastitis and shooting breast pain experienced by women during lactation caused
by Candida albicans?
Carmichael AR, Dixon JM.
The Breast 2001; 11: 88-90.
The value of adjuvant treatment in young women with breast cancer.
Clive S, Dixon JM.
Drugs 2002; 62: 1-11.
Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised
controlled trial: commentary.
Dixon JM.
BMJ 2002; 324: 510.
Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
Miller WR, Dixon JM.
Cancer Control 2002; 9 (suppl): 9-15.
Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast
cancer treatment.
Dixon JM.
Future Drugs: Expert Review of Anticancer Therapy 2002; 2: 267-275.
Latissimus dorsi mini-flap: a technique for extending breast conservation.
Dixon JM, Venizelos B, Chan P.
The Breast 2002; 11: 58-65.
Occult lymph node metastases in patients with ‘node negative’ breast carcinoma treated with
conservative surgery and axillary node sample who subsequently developed axillary
recurrence.
Murray KL, Lambah PA, Anderson TJ, Dixon JM.
The Breast 2002; 11: 249-251.
MIB1 assessments in breast cancers.
Iqbal S, Anderson TJ, Marson LP, Prescott RJ, Dixon JM.
The Breast 2002; 11: 252-256.
Outcome after extended follow-up in a prospective study of operable breast cancer: key
factors and a prognostic index.
Hawkins RA, Tesdale AL, Prescott RJ, Forster T, McIntyre MA, Baker P, Jack WJL,
Chetty U, Dixon JM, Killen ME, Hulme MJ, Miller WR.
British Journal of Cancer 2002; 87: 8-14.
Hormone replacement therapy: is it safe for breast cancer patients.
Dixon JM.
Medical Journal of Australia 2002; 175: 340-341.
Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.
Dixon JM, Anderson TJ, Miller WR.
European Journal of Cancer 2002; 38: 2214-2221.
13
Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively
than tamoxifen.
Bundred NJ, Anderson E, Nicholson RI, Dowsett M, Dixon JM, Robertson JFR.
Anticancer Research 2002; 22: 2317-2320.
Anti-tumour effects of letrozole.
Miller WR, Anderson TJ, Dixon JM.
Cancer Investigation 2002; 20: 15-21.
Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast
in postmenopausal women with large operable breast cancer.
Miller WR, Stuart M, Sahmoud T, Dixon JM.
British Journal of Cancer 2002; 87: 950-955.
Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal
women with large operable breast cancer.
Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR.
British Journal of Cancer 2002; 87: 334-338.
One stop clinics should not be abandoned.
Dixon JM.
BMJ 2002; 324: 507.
The UK national study of magnetic resonance imaging as a method of screening for breast
cancer (MARIBS).
Leach MO, the MARIBS Advisory Group, Staff and Collaborating Centres.
Journal of Experimental and Clinical Cancer Research 2002; 21: 107-114.
Safety issues surrounding the use of aromatase inhibitors in breast cancer
Jackson J, Miller WR, Dixon JM.
Expert Opinion. Drug Safety. 2003; 2(1): 73-86.
Imprint cytology of axillary lymph nodes as an intraoperative diagnostic tool.
Lambah PA, McIntyre MA, Chetty U, Dixon JM.
European Journal of Surgical Oncology 2003; 29: 224-228.
Partial and total breast reconstruction.
Dixon JM.
Journal of the Association of Chartered Physiotherapists in Women’s Health 2003; 92:
25-34.
Does local surgery have a role in the management of stage IV breast cancer?
Carmichael AR, Anderson EDC, Chetty U, Dixon JM.
European Journal of Surgical Oncology 2003; 29: 17-19.
Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic
ionising radiation.
Carmichael A, Sami AS, Dixon JM.
European Journal of Surgical Oncology 2003; 29: 475-479.
Biomarker status as a predictor of response to endocrine treatment in breast cancer.
Dixon JM.
Current Oncology 2003; 10 (suppl 1): S9-13.
14
Pathological features of breast cancer response following neoadjuvant treatment with either
letrozole or tamoxifen.
Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ.
European Journal of Cancer 2003; 39: 462-468.
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Dixon JM, Jackson J, Renshaw L, Miller WR.
Journal of Steroid Biochemistry & Molecular Biology 2003; 86: 295-299.
An integrated view of aromatase and its inhibition.
Miller WR, Anderson TJ, Evans DB, Krause A, Hampton, Dixon JM.
Journal of Steroid Biochemistry and Molecular Biology 2003; 86: 413-421.
Hormone replacement therapy and the breast.
Dixon JM.
Surgical Oncology 2003; 12: 251-263.
Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer:
the need for more clinical research.
Hayward RL, Dixon JM.
Surgical Oncology 2003; 12: 289-304.
The pharmacology of letrozole.
Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS.
Journal of Steroid Biochemistry and Molecular Biology 2003; 87: 34-45.
Exemestane and aromatase inhibitors in the management of advanced breast cancer.
Dixon JM.
Expert Opinion on Pharmacotherapy 2004; 5: 307-316.
Diagnostic delay in breast cancer.
Barber MD, Jack W, Dixon JM.
British Journal of Surgery 2004; 91: 49-53.
A survey of surgical management of the axilla in UK breast cancer patients.
Gaston MS, Dixon JM.
European Journal of Cancer 2004; 40: 1738-1742.
Predictors of non-sentinel lymph node metastasis in breast cancer patients.
Goyal A, Douglas-Jones A, Newcombe RG, Fisher B, Mirimanoff R-O on behalf of
the ALMANAC Trialists Group
European Journal of Cancer 2004; 40: 1731-1737.
Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to
be confident about node-negative status.
Somner JEA, Dixon JM, Thomas St J.
Journal of Clinical Pathology 2004; 57: 845-848.
Neoadjuvant exemestane in the treatment of invasive breast carcinoma in postmenopausal
women.
Dixon JM, Young OE.
Case Studies in Breast Cancer 2004; 3: 3-6.
15
Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for
patients on endocrine therapy (C-PET).
Malinovszky KM, Cameron D, Douglas S, Love CDB, Leonard T, Dixon JM,
Hopwood, Leonard RCF.
The Breast 2004; 13: 363-368.
Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal
women with early breast cancer.
Fallowfield LJ, McGurk R, Dixon JM.
European Journal of Cancer 2004; 40: 2403-2410.
Role of endocrine therapy in the neoadjuvant surgical setting.
Dixon JM.
Annals of Surgical Oncology 2004; 11: 18s-23s.
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive
breast cancers, irrespective of the erbB2 status.
Dixon JM, Jackson J, Hills M, Renshaw L, Cameron DA, Anderson TJ, Miller WR,
Dowsett M.
European Journal of Cancer 2004; 40: 2742-2747.
The scientific value of preoperative studies and how they can be used.
Dixon JM.
Breast Cancer Research and Treatment 2004; 87 (suppl 1): S19-S26.
Biomarker changes during neoadjuvant anastrozole, tamoxifen or the combination: influence
of hormonal status and HER-2 in breast cancer – a study from the IMPACT trialists.
Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre
S, Hills M, Ashley S, Francis S, Walsh G, Smith IE.
Journal of Clinical Oncology 2005; 23 (11): 2477-2492.
Screening with magnetic resonance imaging and mammography of a UK population at high
familial risk of breast cancer: a prospective multicentre cohort study (MARBIS).
MARIBS Study Group.
The Lancet 2005; 365: 1769-1778.
Short-term changes in Ki67 during neoadjuvant treatment of primary breast cancer with
anastrozole or tamoxifen alone or combined correlate with recurrence free survival.
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I,
Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, IMPACT Trialists.
Clinical Cancer Research 2005; 11: 951s-958s.
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both
in combination: the immediate preoperative anastrozole, tamoxifen or combined with
tamoxifen (IMPACT) multicenter double-blind randomised trial.
Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis
S, Boeddinghaus I, Walsh G.
Journal of Clinical Oncology 2005; 23: 5108-5116.
Surgical issues surrounding the use of aromatase inhibitors.
Dixon JM.
Journal of Steroid Biochemistry and Molecular Biology 2005; 95: 97-103.
16
Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and
specificity analysis.
Warren RL, Pointon L, Thompson D, Hoff R, Gilbert FJ, Padhani A, Easton D,
Lakhani SR, Leach MO on behalf of the UK Magnetic Resonance Imaging in Breast
Screening (MARIBS) Study Group.
Radiology 2005; 236: 779-788.
Current management of breast cancer: a surgeon’s perspective.
Murray EL, Dixon JM.
MIMS Advances: Breast Cancer September 2005, 2-5.
Aromatase inhibitors: cellular and molecular effects.
Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon
JM.
Journal of Steroid Biochemistry and Molecular Biology 2005; 95: 83-89.
Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in twothirds of breast tumours.
Tomlinson VAL, Newberry HJ, Wray NR, Jackson J, Larionov A, Miller WR, Dixon
JM, Abbott CM.
BMC Cancer 2005; 5: 113.
Attitudes of breast cancer professionals to conventional and telemedicine-delivered
multidisciplinary breast meetings.
Fielding GR, Macnab M, Swann S, Kunkler IH, Brebner J, Prescott RJ, Maclean JR,
Chetty U, Neades GTN, Walls A, Bowman A, Dixon JM, Gardner T, Smith M, Lee
MJ, Lee RJ.
Journal of Telemedicine and Telecare 2005; 11 (suppl 2: S2: 29-34.
Comparisons and clinical outcomes in breast cancer: neoadjuvant tamoxifen and aromatase
inhibitors.
Dixon JM, Macaskill JE, Jackson J, Renshaw L, Miller WR,
<http://www.siicsalud.com/des/des046/05n21019i.htm>
Breast cancer (non-metastatic).
Dixon JM, Rodger A, Sebbing J.
Clinical Evidence Concise 2005; 14: 555-560.
A comprehensive approach for evaluating telemedicine-delivered multidisciplinary breast
cancer meetings in Southern Scotland.
Kunkler IH, Fielding RG, Brebner J, Prescott RJ, Maclean R, Cairns J, Chetty U,
Neades GT, Walls A, Bowman A, Dixon JM, Gardner T, Smith M, MacCoubrey J,
Lee AJ, Swann S, Macnab M, Wilson J, Nawroz I.
Journal of Telemedicine and Telecare 2005; 11 (suppl 1): 71-73.
Screening for breast cancer.
Dixon JM.
BMJ 2006; 332: 499-500
Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies.
Dixon JM, Bundred NJ.
European Journal of Surgical Oncology 2006; 32: 123-125.
17
The prevention, detection and management of breast cancer.
Houssami N, Cuzick J, Dixon JM.
Medical Journal of Australia 2006; 184 (5): 230-234.
Surgeons’ views on multi-disciplinary breast meetings.
Macaskill EJ, Thrush S, Walker EM, Dixon JM.
European Journal of Cancer 2006; 42: 905-908.
Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and
effects of treatment.
Miller WR, Anderson TJ, Dixon JM, Saunders PTK.
British Journal of Cancer 2006; 94: 1333-1338.
Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Dixon JM.
Expert Review of Anticancer Therapy 2006; 6 (6): 849-859.
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary
breast cancer after neoadjuvant letrozole.
Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D,
Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM.
Journal of Clinical Oncology 2006; 24 (19): 3019-3025.
Consensus Conference on Breast Conservation, Milan, Italy, May 2005.
Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-Kobrunner
SH, Holland R, Hughes KS, Mansel RE, Margolese R, Mendelson ES, Olivotto IA,
Palazzo JP, Solin LJ on behalf of the conference committee.
Breast Journal 2006; 12 (4): 398-407.
Cost effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray
mammography of women at high familial risk of breast cancer.
Griebsh I, Brown J, Boggis C, Dixon A, Dixon JM, Easton D, Eeles R, Evans DG,
Gilbert FJ, Hawnaur J, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR,
Pointon LJ, Potterton J, Thompson D, Turnbull LW, Walker LG, Warren R, Leach
MO for the UK Magnetic Resonance Imaging in Breast Screening (MARIBS) Study
Group.
British Journal of Cancer 2006; 95: 801-810.
Diagnosis and management of benign breast disease in older women.
Houssami N, Dixon JM.
Geriatrics and Aging 2006; 9 (9): 600-606.
Aromatase inhibitors in early breast cancer: a variety of treatment strategies.
Dixon JM.
Expert Opinion in Pharmacotherapy 2006; 7 (18): 2465-2479.
Group dynamics within telemedicine delivered and standard multidisciplinary team meetings:
results from the TELEMAM randomised trial.
Kunkler IH, Fielding RG, Macnab M, Swann S, Brebner J, Prescott RJ, MacLean JR,
Chetty U, Bowman A, Neades G, Dixon JM, Smith M, Walls A, Cairns J, Lee RJ, Lee
AJ, Gardner T.
Journal of Telemedicine and Telecare 2006; 12 (suppl 3): 55-58.
18
Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with
letrozole.
Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ.
British Journal of Cancer 2006; 94: 1051-1056.
Consensus Conference on Breast Conservation, Milan, Italy, May 2005.
Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-Kobrunner
SH, Holland R, Hughes KS, Mansel RE, Margolese R, Mendelson ES, Olivotto IA,
Palazzo JP, Solin LJ on behalf of the conference committee.
International Journal of Radiation Oncology, Biology & Physics 2006; 65(5): 12811288.
Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in
their transcriptome data structures.
Zhu Y, Wang A, Liu MC, Xwart A, Lee RY, Gallagher A, Wang Y, Miller WR,
Dixon JM, Clarke R.
International Journal of Oncology 2006; 29(6): 1581-1589.
Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced
hormone receptor-positive breast cancer.
Macaskill EJ, Renshaw L, Dixon JM.
The Oncologist 2006; 11(10): 1081-1088.
Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in
operable breast cancer: the ALMANAC trial.
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou
C, Horgan K, Bundred NJ, Monypenny I, England D, Sibbering M, Abdullah TI, Barr
L, Chetty U, Sinnett D, Fleissig A, Clarke D, Ell PJ.
Journal of the National Cancer Institute 2006; 98(9): 599-609.
Post-operative arm morbidity and quality of life: results of the ALMANAC randomised trial
comparing sentinel node biopsy with standard axillary treatment in the management of
patients with early breast cancer.
Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM,
Kissin M, Mansel RE.
Breast Cancer Research and Treatment 2006; 95(3): 279-293.
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast
cancer.
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghause I,
Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A’Hern R.
Clinical Cancer Research 2006; 12 (3): 1024s-1030s.
Consensus Conference on Breast Conservation, Milan, Italy, May 2005.
Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-Kobrunner
SH, Holland R, Hughes KS, Mansel RE, Margolese R, Mendelson ES, Olivotto IA,
Palazzo JP, Solin LJ on behalf of the conference committee.
Journal of the American College of Surgeons 2006; 203(2): 198-207.
Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast
cancer – results of the ALMANAC validation phase.
Goyal A, Newcombe RG, Chhabra A, Mansel RE on behalf of the ALMANAC
Trialists Group.
19
Breast Cancer Research and Treatment 2006; 99: 203-208.
A review of current practices in breast conservation surgery in the UK.
Young OE, Valassiadou, Dixon JM.
Annals of the Royal College of Surgeons of England 2007; 89(2): 118-123.
Changing pattern of the detection of locorergional relapse in breast cancer: the Edinburgh
experience.
Montgomery DA, Krupa K, Jack WJL, Kerr GR, Kunkler IH, Thomas J, Dixon JM.
British Journal of Cancer 2007; 96: 1802-1807.
Breast abscess.
Dixon JM.
British Journal of Hospital Medicine 2007; 68: 315-320.
For the use of ultrasound by surgeons.
Dixon JM, Macaskill JE.
Breast Cancer Online 2007; 10(3): 1-3.
Neoadjuvant use of endocrine therapy in breast cancer.
Macaskill EJ, Dixon JM.
The Breast 2007; 13(3): 243-250.
Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common
association between letrozole therapy and central scarring.
Thomas J StJ, Julian HS, Green, RV, Cameron DA, Dixon JM.
Histopathology 2007; 51: 219-226.
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S,
Larionov A, Young OE, White S, Miler WR, Evans DB, Dowsett M.
Breast Cancer Research 2007; 9: R37.
DCIS and aromatase inhibitors.
Dixon JM, Faratian D, White S, Renshaw L, Murray J, Young O, Macaskill EJ,
Williams L, Thomas J, Evans DB.
Journal of Steroid Biochemistry & Molecular Biology 2007; 106: 173-179.
Hormone replacement therapy.
Dixon JM.
Menopause Digest 2007.
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for
primary breast cancer.
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre S,
Hills M, Walsh G.
Journal of the National Cancer Institute 2007; 99(2): 167-170.
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor
letrozole.
Miller WR, Larionov A, Renshaw L, Anderson TJ, White S, Murray J, Hampton G,
Walker JR, Ho, S, Krause A, Evans DB, Dixon JM.
Pharmacogenetics and Genomics 2007; 17(10): 813-826.
20
A luminal breast cancer genome atlas: progress and barriers.
Ellis MJ, Dixon JM, Dowsett M, Nagarajan R, Mardis E.
Journal of Steroid Biochemistry & Molecular Pathology 2007; 106: 125-129.
TELEMAM: A cluster randomised trial to assess the use of telemedicine in multi-disciplinary
breast cancer decision making.
Kunkler IH, Prescott RJ, Lee RJ, Brebner JA, Cairns JA, Fielding RG, Bowman A,
Neades G, Walls ADF, Chetty U, Dixon JM, Smith ME, Gardner TW, Macnab M,
Swann S, Maclean JR.
European Journal of Cancer 2007; 43; 2506-2514.
Does presurgical treatment destroy important prognostic information?
Dixon JM.
Breast Cancer Research 2007; 9 (suppl 2): S17.
Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive
primary breast cancer.
Young OE, Renshaw L, Macaskill EJ, White S, Faratian D, Thomas JStJ, Dixon JM.
European Journal of Cancer 2008; 44: 391-399.
Follow-up after breast cancer.
Dixon JM, Montgomery DA.
BMJ 2008; 336: 107-108.
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole
in postmenopausal women with breast cancer.
Dixon JM, Renshaw L, Young OE, Murray J, Macaskill EJ, McHugh M, Folkerd E,
Cameron DA, A’Hern RP, Dowsett M.
Journal of Clinical Oncology 2008; 26(10): 1671-1676.
Role of ErbB2 in selection for adjuvant tamoxifen or aromatase inhibitors.
Dixon JM.
Women’s Health 2008; 4(3): 229-231.
Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM.
Expert Review of Anticancer Therapy 2008; 8(3); 453-463.
Breast Problems
Dixon JM.
Pulse, 2008; 14th May: 32-33.
Accuracy and surgical impact of MRI in breast cancer staging: systematic review and metaanalysis in detection of multifocal and multicentric cancer.
Houssami N, Ciatto S, Macaskill P, Lord SJ, Warren RM, Dixon JM, Irwig L.
Journal of Clinical Oncology 2008; 26(19): 3248-3258.
Published online 12th May 2008: doi/10.1200/JCO.2007.152108.
Predictors of mastectomy in a certified breast center – the surgeon is an independent risk
factor.
Dixon JM, Mak C.
The Breast Journal 2008; 14(4): 321-323.
Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Dixon JM.
21
The Breast 2008; 17: 353-360.
Use of enoxaparin results in more haemorrhagic complications after breast surgery than
unfractionated heparin.
Hardy RG, Williams L, Dixon JM.
British Journal of Surgery 2008; 95: 834-836
Published online 18th April 2008: doi: 10.1002/bjs.6203
A pilot study of compositional analysis of the breast cancer estimation of breast
mammographic density using three-dimensional T1-weighted magnetic resonance imaging.
Khazen M, Warren RML, Boggis CRM, Bryant EC, Reed S, Warsi I, Pointon LJ,
Kwan-Lim GE, Thompson D, Eeles R, Easton D, Evans DG, Leach MO for the
collaborators in the United Kingdom Medical Research Council Magnetic Resonance
Imaging in Breast Screening (MARIBS) Study (Dixon JM and others).
Cancer Epidemiology Biomarkers & Prevention 2008; 17: 2268-2274.
Effects of switching from one nonsteroidal aromatase inhibitor to another in a
postmenopausal patient with hormone-sensitive breast cancer: a case study.
Dixon JM.
American Journal of Hematology/Oncology 2008; 7(9): 381-387.
Increase in response rate by prolonged treatment with neoadjuvant letrozole.
Dixon JM, Renshaw L, Macaskill EJ, Young OE, Murray J, Cameron DA, Kerr GR,
Evans DB, Miller WR.
Breast Cancer Research and Treatment 2009; 113: 145-151.
Predicting response and resistance to endocrine therapy: profiling patients on aromatase
inhibitors.
Miller WR, Larionov A, Anderson TJ, Walker JR, Krause A, Evans DB, Dixon JM.
Cancer 2009; in press.
Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
Jones RJ, Young O, Renshaw L, Jacobs V, Fennell M, Marshall A, Green TP, Elvin P,
Womack C, Clack G, Dixon JM.
Breast Cancer Research and Treatment 2009; in press.
A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive
breast cancers in postmenopausal women.
Murray J, Young OE, Renshaw L, White S, Williams L, Evans DB, Thomas JStJ,
Dowsett M, Dixon JM.
Breast Cancer Research and Treatment 2009; in press.
Published online 12th June 2008: doi/10.1007/s10549-008-0027-0
Breast cancer risk reduction and membrane-bound catechol o-methyltransferase genetic
polymorphisms.
Yuan J, Olson JE, Zhang J, Hildebrandt M, Wang L, Ingle JN, Fredericksen Z, Sellers
TA, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Yon-Dschun K, Chang J,
Wang-Gohrke S, Schaid DJ, Miller WR, Dixon JM.
Cancer Research 2009; in press.
Steroid receptor coactivator-1 and Peroxisome-proliferator activated receptor γ coactivator-1α
increase in breast cancer responsive to aromatase inhibitors.
Hauglid M, Haugan Moi LL, Dixon JM, Geisler J, Lokkeviok E, Miler WR, Lien EA,
Lonning PE, Mellgren G.
Cancer Research 2009; in press.
22
Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Ortmann O, Cufer T, Dixon JM, Maass N, Pagani O, Pronzato P, Semiglazov V,
Spano J-P, Vrdoljak E, Wildiers H.
The Breast 2009; in press.
Gene expression profiles differentiating between breast cancers clinically responsive or
resistant to letrozole.
Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T,
Evans DB, Dixon JM.
Journal of Clinical Oncology 2009; in press.
Chapters in Books
Cystic disease of the breast.
Dixon JM.
In:
Benign Breast Disease
Eds: Taylor and Smallwood.
Edward Arnold 1990; pp 66-84.
Cystic disease and fibroadenoma of the breast: natural history and relation to breast cancer
risk.
Dixon JM.
In:
British Medical Bulletin. Breast Cancer - New Approaches.
Eds: Stewart, Anderson and Forrest.
Churchill Livingstone, Edinburgh 1991; pp 258-271.
Benign breast disease
Dixon JM.
In:
A New Airds Companion to Surgical Studies.
Eds: Bernand and Young.
Churchill Livingstone, Edinburgh 1992; pp 811-826.
Breast surgery
Dixon JM
In:
Infection in Surgical Practice.
Ed:
Taylor I
Oxford University Press, Oxford 1992; pp 187-196.
Fine needle aspiration cytology: How I do it.
Dixon JM.
In:
Recent Developments in the Study of Benign Breast Disease:
Proceedings of the 4th International Benign Breast Disease Symposium.
Ed:
Mansel RE
Parthenon Publishing Group, New Jersey 1992; pp 197-201.
Breast conservation surgery.
Dixon JM.
Recent Advances in Surgery 1993; 16: 43-61.
Diagnosis of benign lesions in a modern breast clinic.
Dixon JM.
23
In:
Recent Developments in the Study of Benign Breast Disease. The
Proceedings of the 5th International Benign Breast Disease Symposium
Ed:
Mansel RE
Parthenon Publishing, London 1994; pp 33-38
Natural history of fibroadenoma of the breast.
Dobie V, Walsh J, Lamb J and Dixon JM, .
In:
Recent Developments in the Study of Benign Breast Disease. The
Proceedings of the 5th International Benign Breast Disease Symposium
Ed:
Mansel RE
Parthenon Publishing, London 1994; pp 75-81
Smoking in patients with periductal mastitis and duct ectasia.
Dixon JM, RaviSekar O, Waverely A and Chetty U.
In:
Recent Developments in the Study of Benign Breast Disease. The
Proceedings of the 5th International Benign Breast Disease Symposium
Ed:
Mansel RE
Parthenon Publishing, London 1994; pp 215-219
Effects of spironolactone, danazol and Efamast on the uptake of tritiated
dehydroepiandrosterone sulphate into human breast cyst fluid.
Dixon JM, Telford J and Miller WR.
In:
Recent Developments in the Study of Benign Breast Disease. The
Proceedings of the 5th International Benign Breast Disease Symposium
Ed:
Mansel RE
Parthenon Publishing, London 1994; pp 265-270
Breast
Dixon JM.
In:
Color Atlas of Surgical Diagnosis.
Eds: Greig JD, Garden OJ.
Mosby-Wolfe, London 1996, pp 24-36.
Ductal Carcinoma in situ: the Edinburgh experience.
Dixon JM and Anderson EDC.
In:
Ductal carcinoma in situ: a diagnostic and therapeutic dilemma.
Ed:
Silverstein MJ.
Williams and Wilkins, USA 1997, pp 379-384.
Hormones and Chemotherapy.
Dixon JM and Leonard RCF.
In:
A Companion to Specialist Surgical Practice: Breast and Endocrine Surgery
Ed:
Farndon JR.
WB Saunders, London 1997, pp 275-308.
Benign Breast Disease (Invited Comment).
Dixon JM.
In:
Crucial Controversies in Surgery.
Eds: Schein M, Wise L.
Karger Landes Systems, Basel 1998, pp 106-112.
Benign breast disease
24
Dixon JM.
In:
The New Aird’s Companion to Surgical Studies, 2nd Edition
Eds: Bernand KG and Young AE.
Churchill Livingstone, Edinburgh 1998, pp 631-663.
Who should provide the diagnostic service?
Dixon JM.
In:
Key Advances in the Effective Management of Breast Cancer.
Eds: Baum M, Spittle M.
Royal Society of Medicine Press, London 1999; pp 11-13.
Neoadjuvant endocrine treatment: the Edinburgh experience.
Miller WR, Anderson TJ, Hawkins RA, Keen J, Dixon JM.
In:
Primary Medical Therapy for Breast Cancer: Clinical and Biological
Aspects. European School of Oncology Scientific Updates, 4.
Eds: Veronesi U, Aapro MS
Elsevier Science, The Netherlands, 1999, pp 89-99.
Management of disorders of the ductal system and infections
Dixon JM and Bundred NJ.
In:
Diseases of the Breast: 2nd Edition
Eds: Harris J, Lippman ME, Morrow M and Osborne CK
Lippincott Williams and Wilkins, Philadelphia 1999; pp 47-55.
Neoadjuvant endocrine therapy.
Dixon JM.
In:
Aromatase Inhibition and Breast Cancer.
Eds: Miller WR, Santen RJ.
Marcel Dekker, Inc, New York, 2000, pp103-116.
Induction and suppression of aromatase by inhibitors.
Miller WR, Vidya R, Mullen P, Dixon JM.
In:
Aromatase Inhibition and Breast Cancer.
Eds: Miller WR, Santen RJ.
Marcel Dekker, Inc, New York, 2000, pp 213-226.
Benign breast disease (chapter 5.1)
Dixon JM.
In:
Textbook of Surgery: Breast/Endocrine Section.
Ed:
Williams RCN.
Harcourt Health Sciences, London 2000.
Breast cancer: epidemiology (chapter 5.2)
Dixon JM.
In:
Textbook of Surgery: Breast/Endocrine Section.
Ed:
Williams RCN.
Harcourt Health Sciences, London 2000.
Recurrent periareolar sepsis (chapter 5.11.1)
Dixon JM.
In:
Textbook of Surgery: Breast/Endocrine Section.
25
Ed:
Williams RCN.
Harcourt Health Sciences, London 2000.
Blood-stained discharge from a single nipple duct (chapter 5.11.2)
Dixon JM.
In:
Textbook of Surgery: Breast/Endocrine Section.
Ed:
Williams RCN.
Harcourt Health Sciences, London 2000.
Mass in a young woman: observe or excise? (Chapter 5.11.3)
Dixon JM.
In:
Textbook of Surgery: Breast/Endocrine Section.
Ed:
Williams RCN.
Harcourt Health Sciences, London 2000.
Symptoms, assessment and guidelines for referral.
Dixon JM, Mansel RE.
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 1-9.
Congenital problems and aberrations of normal development and involution.
Dixon JM, Mansel RE.
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 10-15.
Breast infection.
Dixon JM
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 21-25.
Breast cancer – epidemiology, risk factors and genetics.
McPherson K, Steel CM, Dixon JM
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 26-32.
Management of regional nodes in breast cancer.
Bundred NJ, Morgan DAL, Dixon JM
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 44-49.
Breast cancer: treatment of elderly patients and uncommon conditions.
Dixon JM, Sainsbury JRC, Rodger A.
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 50-54.
Locally advanced breast cancer.
Rodger A, Leonard RCF, Dixon JM
26
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 61-64.
Metastatic breast cancer
Leonard RCF, Rodger A, Dixon JM
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 65-71.
Clinical trials and management of breast cancer.
Dixon JM, Baum M
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 78-84.
Carcinoma in situ.
Page DL, Steel CM, Dixon JM
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 90-96.
Breast reconstruction.
Watson JD, Sainsbury JRC, Dixon JM
In:
ABC of Breast Diseases, 2nd Edition
Ed:
Dixon JM.
BMJ Books, London 2000, pp 97-103.
Hormones and Chemotherapy.
Dixon JM and Leonard RCF.
In:
A Companion to Specialist Surgical Practice: Breast and Endocrine Surgery,
2nd edition
Ed:
Farndon JR.
WB Saunders, London 2001, pp 107-146.
Breast reconstruction after mastectomy.
Dixon JM.
In:
Breast Cancer: Diagnosis and Management.
Ed:
Dixon JM.
Elsevier Science, Oxford, 2001; pp. 207-213.
Neoadjuvant endocrine therapy.
Dixon JM.
In:
Breast Cancer: Diagnosis and Management.
Ed:
Dixon JM.
Elsevier Science, Oxford, 2001; pp. 305-309.
Breast cancer in elderly patients.
Dixon JM, Aapro M.
In:
Breast Cancer: Diagnosis and Management.
Ed:
Dixon JM.
Elsevier Science, Oxford, 2001; 369-375.
27
Locally advanced breast cancer.
Dixon JM.
In:
Breast Cancer: Diagnosis and Management.
Ed:
Dixon JM.
Elsevier Science, Oxford, 2001; pp. 395-403.
The Breast
Dixon JM.
In:
Principles and Practice of Surgery.
Eds: Garden OJ, Forsythe JLR, Bradbury AW.
Churchill Livingstone, Edinburgh, 2002, pp396-422.
Neoadjuvant therapy: surgical perspectives.
Dixon JM.
In:
Endocrine Therapy in Breast Cancer.
Eds: Miller WR, Ingle JN.
Marcel Dekker Inc, New York, 2002; pp 197-212.
Neoadjuvant therapy: prediction of response.
Miller WR, Anderson TJ, Iqbal S, Dixon JM.
In:
Endocrine Therapy in Breast Cancer.
Eds: Miller WR, Ingle JN.
Marcel Dekker Inc, New York, 2002; pp 223-229.
Adjuvant treatment in breast cancer.
Dixon JM.
In:
Recent Advances in Surgery.
Eds: Johnson C, Taylor I.
Royal Society of Medicine Press, London, 2002, pp 191-204.
Ductal carcinoma in situ: the Edinburgh experience.
Dixon JM.
In:
Ductal Carcinoma of the Breast, second edition
Ed:
Silverstein MJ.
Lippincott Williams & Wilkins, Philadelphia 2002, pp 343-347.
Breast Disease: Diagnostic Methods
Dixon JM.
In:
Surgical Practice
Eds: Majid AA, Kingsnorth AN
Greenwich Medical Media, London 2002; pp 379-385.
Breast cancer: non-metastatic.
Dixon JM, Gregory K, Johnston S, Rodger A.
Clinical Evidence 2002; 7: 1603-1630.
Breast cancer: non-metastatic.
Dixon JM, Gregory K, Johnston S, Rodger A.
Clinical Evidence 2002; 8: 1811-1839.
Neoadjuvant use of anastrozole.
Dixon JM, Miller WR, Anderson TJ.
In:
History and Advancement of Anastrozole in the Treatment of Breast Cancer.
Eds: Buzdar A, Baum M.
28
Royal Society of Medicine 2003; pp 15-19.
Breast cancer (non-metastatic)
Dixon JM, Gregory K, Johnston S, Rodger A.
Clinical Evidence 2003; 9: 1940-1970.
Breast cancer (non-metastatic)
Dixon JM, Gregory K, Johnston S, Rodger A.
Clinical Evidence 2003; 10: 376-379.
Breast cancer (non-metastatic).
Dixon JM, Gregory K, Johnston S, Rodger A.
Clinical Evidence 2004; 12: 2449-2482.
Breast cancer (non-metastatic).
Dixon JM, Gregory K, Johnston S, Rodger A.
Clinical Evidence 2004; 11: 2300-2333.
Neoadjuvant therapy in postmenopausal women.
Dixon JM.
In:
Advances in Endocrine Therapy of Breast Cancer.
Eds: Ingle JN, Dowsett M.
Marcel Dekker, New York, 2004.
Management of disorders of the ductal system and infections.
Dixon JM, Bundred NJ.
In:
Diseases of the Breast, 3rd Edition.
Eds: Harris JR, Lippman ME, Morrow M, Osborne CK.
Lippincott Williams & Wilkins, Philaldephia, 2004, pp 47-56.
Breast disease (benign)
Dixon JM.
In:
A New Aird’s Companion in Surgical Studies. 3rd Edition.
Eds: Bernand KG, Young AE, Lucas J.
Elsevier Ltd, Oxford 2005, pp 506-517.
Symptoms, assessment and guidelines for referral.
Dixon JM, Thomas J.
In:
ABC of Breast Diseases, 3rd Edition.
Ed:
Dixon JM.
BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 1-7.
Congenital problems and aberrations of normal development and involution.
Dixon JM, Thomas J.
In:
ABC of Breast Diseases, 3rd Edition.
Ed:
Dixon JM.
BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 8-14.
Breast infection.
Dixon JM.
In:
ABC of Breast Diseases, 3rd Edition.
Ed:
Dixon JM.
BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 19-23.
29
Breast cancer: epidemiology, risk factors and genetics.
McPherson K, Steel CM, Dixon JM.
In:
ABC of Breast Diseases, 3rd Edition.
Ed:
Dixon JM.
BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 24-29.
Management of regional nodes in breast cancer.
Bundred NJ, Rodger A, Dixon JM.
In:
ABC of Breast Diseases, 3rd Edition.
Ed:
Dixon JM.
BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 42-47.
Breast cancer: treatment of elderly patients and uncommon conditions.
Dixon JM, Sainsbury JRC, Rodger A.
In:
ABC of Breast Diseases, 3rd Edition.
Ed:
Dixon JM.
BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 48-53.
Locally advanced breast cancer.
Rodger A, Leonard RCF, Dixon JM.
In:
ABC of Breast Diseases, 3rd Edition.
Ed:
Dixon JM.
BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 65-69.
Metastatic breast cancer.
Leonard RCF, Rodger A, Dixon JM.
In:
ABC of Breast Diseases, 3rd Edition.
Ed:
Dixon JM.
BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 70-76.
Breast reconstruction.
Dixon JM, Watson JD, Sainsbury JRC, Weiler-Mithoff EM.
In:
ABC of Breast Diseases, 3rd Edition.
Ed:
Dixon JM.
BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 100-106.
Breast cancer (non-metastatic).
Dixon JM, Rodger A, Sebbing J.
In:
Clinical Evidence Concise
Ed:
Onwude J.
BMJ Publishing Group, London, 2005 (14), pp 555-560.
Neoadjuvant treatment.
Dixon JM, Macaskill EJ.
In:
Aromatase Inhibitors for the Treatment of Breast Cancer.
Ed:
Ellis MJ.
CMP Healthcare Media, New York, 2005, pp 55-72.
Clinical studies with letrozole.
Dixon JM.
In:
Aromatase Inhibitors.
Ed:
Furr BJA.
30
Birkhauser, Basel. 2005, pp 65-94.
Breast conserving surgery: the balance between good cosmesis and local control.
Dixon JM.
In:
A Companion to Specialist Surgical Practice: Volume 5: Breast Disease, 3rd
Edition
Volume Ed: Dixon JM.
Elsevier Ltd., Edinburgh 2006, pp 47-64.
Benign breast disease.
Thrush S, Dixon JM.
In:
A Companion to Specialist Surgical Practice: Volume 5: Breast Disease, 3rd
Edition
Volume Ed: Dixon JM.
Elsevier Ltd., Edinburgh 2006, pp 251-268.
Aromatase inhibitors in the adjuvant and extended adjuvant breast cancer settings: a review of
new data.
Dixon JM.
In:
The Association of Breast Surgery at BASO Yearbook
Ed:
Sibbering M.
BASO, London, 2006, pp 28-32.
Neoadjuvant breast cancer: hormone therapy.
Dixon JM, Jackson J, Miller WR,
In:
Anti-Aromatase Therapy for Breast Cancer – New Developments.
Eds: Sasano K, Toi M.
Medical Science Publication Inc, Tokyo, 2006.
Breast conserving surgery.
Dixon JM, Soon PSH.
In:
Mastery of Surgery
Eds: Fischer JE, Bland KI, Callery MP, Clagett GP, Jones DB, LoGerfo FW, Seeger
JM.
Lippincott Williams & Wilkins, Philadelphia, 2007, pp 502-516.
The Breast.
Dixon JM.
In:
Principles and Practice of Surgery
Eds: Garden OJ, Bradbury AW, Forsythe JRL, Parks RW.
Churchill Livingstone Elsevier, Edinburgh, 2007, pp 365-389.
Clinical studies with letrozole
Dixon JM.
In:
Aromatase Inhibitors. 2nd Edition.
Ed:
Furr BA.
Birkhauser, Basel, 2008, pp 69-100.
Books
Handbook of Diseases of the Breast
31
Dixon JM and Sainsbury JRC.
Churchill Livingstone, London, 1993.
ABC of Breast Diseases
Edited by Dixon JM.
BMJ Publishing Group, London 1995.
Electropotentials in the clinical assessment of breast cancer.
Edited by Dixon JM.
European School of Oncology Monographs, Springer Verlag, Germany 1995.
Handbook of Diseases of the Breast, 2nd Edition
Dixon JM and Sainsbury JRC.
Churchill Livingstone, London, 1998.
Breast Disease: A Problem-Based Approach
Dixon JM and Morrow M.
WB Saunders, London, 1999.
British Medical Association Family Doctor Guide to Breast Disorders
Dixon JM and Leonard RCF.
Dorling Kindersley, London, 1999.
Clinical Evidence
Primary Breast Cancer Section Editor: Dixon JM.
BMJ Publishing Group, London, 1999, pp 385-397.
Understanding Breast Disorders
Dixon JM and Leonard RCF.
Family Doctor Publications (BMJ) 1999.
Clinical Evidence: Second Issue
Breast Cancer: Non-Metastatic: Section Editor: Dixon JM.
BMJ Publishing Group, London, 1999, pp 687-699.
Clinical Evidence: Third Issue
Breast cancer: non-metastatic: Section Editor: Dixon JM
BMJ Publishing Group, London 2000, pp 863-881.
ABC of Breast Diseases, 2nd Edition
Ed: Dixon JM.
BMJ Publishing Group, London, 2000.
Clinical Evidence: Fourth Issue
Women’s Health: Breast Cancer: Section Editor: Dixon JM
BMJ Publishing Group, London, 2000, pp1000-1044.
Clinical Evidence: Fifth Issue
Women’s Health: Breast Cancer: Section Editor: Dixon JM
BMJ Publishing Group, London, 2001, pp 1196-1253
Breast Disease: Diagnosis and Management
Ed: Dixon JM.
Elsevier Science, Oxford, 2001.
32
Clinical Evidence Concise: Sixth Issue.
Women’s Health: Breast Cancer: Non-Metastatic: Section Editor: Dixon JM.
BMJ Publishing Group, London, 2001, pp
Clinical Evidence Concise: Seventh Issue
Women’s Health: Breast Cancer: Non-Metastatic: Section Editor: Dixon JM
BMJ Publishing Group, London, 2002: pp 311-315.
Clinical Evidence Concise: Eighth Issue
Woman’s Health: Breast Cancer: Non-Metastatic. Section Editor: Dixon JM
BMJ Publishing Group, London 2002, pp 355-359
Clinical Evidence Concise: Nineth Issue
Woman’s Health: Breast Cancer: Non-Metastatic. Section Editor: Dixon JM
BMJ Publishing Group, London 2003
Clinical Evidence Concise: Tenth Issue
Woman’s Health: Breast Cancer: Non-Metastatic. Section Editor: Dixon JM
BMJ Publishing Group, London 2003, pp 376-379.
Clinical Evidence Concise: Eleventh Issue
Woman’s Health: Breast Cancer: Non-Metastatic. Section Editor: Dixon JM
BMJ Publishing Group, London 2004, pp 434-438
Clinical Evidence Concise: Twelfth Issue
Women’s Health: Breast Cancer: Non-Metastatic. Section Editor: Dixon JM.
BMJ Publishing Group, London 2004, pp 472-476.
Understanding Breast Screening.
Dixon JM in association with CancerBACUP.
CancerBACUP, London 2004.
Understanding Breast Cancer.
Dixon JM in association with CancerBACUP.
CancerBACUP, London 2005.
Clinical Evidence Concise: Thirteenth Issue
Women’s Health: Breast Cancer: Non-Metastatic. Section Editor: Dixon JM.
BMJ Publishing Group, London 2005, pp 506-511.
ABC of Breast Diseases, 3rd Edition
Ed: Dixon JM.
BMJ Books, Blackwell Publishing Ltd, London, 2006.
A Companion to Specialist Surgical Practice: Volume 5: Breast Disease, 3rd Edition
Volume Ed: Dixon JM.
Elsevier Ltd., Edinburgh 2006.
Understanding Breast Cancer.
Dixon JM.
Family Doctor Publications, London 2009; in press.
33